Session Type: ACR Poster Session B
Session Time: 9:00AM-11:00AM
Background/Purpose: In patients with rheumatoid arthritis (RA), in whom methotrexate (MTX) is not inducing remission or at least low disease activity, or is not tolerated, leflunomide is one conventional synthetic DMARD option that is still commonly used in some countries. We thus investigated whether real life patients with RA benefit from instituting leflunomide after methotrexate.
Methods: The clinical data of all RA patients who had at least once received leflunomide, and who agreed to the pseudonymized analysis of their data (approved by the local ethics committee), were analyzed from the time of leflunomide initiation on to the time of stopping leflunomide or the last visit in 2015, which ever came first.
Results: 144 RA patients treated with leflunomide were identified. Of these, 86 received leflunomide after MTX had failed as a first line DMARD, and 8 received leflunomide as a first line DMARD. 50 patients had another first line therapy. Of the first line leflunomide patients 3 (38%) were still on leflunomide at the last visit, as compared to 6 of the 43 patients (14%) who were switched from MTX to leflunomide, and 0 of the 27 patients in whom leflunomide was added to MTX (p<0.01 vs 1
To cite this abstract in AMA style:Weigt G, Erler A, Aringer M. In Real Life Rheumatoid Arthritis Patients, Leflunomide Has Limited Impact As a Second Line DMARD after Methotrexate [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/in-real-life-rheumatoid-arthritis-patients-leflunomide-has-limited-impact-as-a-second-line-dmard-after-methotrexate/. Accessed November 27, 2020.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-real-life-rheumatoid-arthritis-patients-leflunomide-has-limited-impact-as-a-second-line-dmard-after-methotrexate/